Translating into Русский. The English version is shown until it is ready.
Alteogen to absorb subsidiary Alteogen Biologics in small-scale merger
Коротко
Alteogen said its board decided on Oct 6 to absorb its 62.9%-owned subsidiary Alteogen Biologics in a small-scale merger at a ratio of 1 to 0.1679581, issuing 600,477 new Alteogen shares. Alteogen Biologics holds the completed global phase 3 trial and European approval for ALT-L9, an Aylia biosimilar, and is developing the macular degeneration candidate ALTS-OP01. The two companies are to sign the merger contract on Oct 7, with the merger date set for Dec 29.
Читать полностью 2 мин чтения
Alteogen said its board decided on Oct 6 to absorb its subsidiary Alteogen Biologics in a small-scale merger, according to disclosures reported by Yonhap, Chosun Ilbo and other outlets. Alteogen holds 62.9% of Alteogen Biologics. Under the disclosed terms the merger ratio is 1 to 0.1679581, and 600,477 new Alteogen shares will be issued to Alteogen Biologics shareholders, with no new shares allotted for the 62.9% stake Alteogen already holds. The company said the ratio was calculated from Alteogen's base price and an external valuation of Alteogen Biologics' intrinsic value. [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ]
Alteogen Biologics brings the completed global phase 3 trial and European approval for ALT-L9, an Aylia biosimilar whose product names Yonhap gave as Irluxbi and Aizenpi injection. It handles sales and marketing of pharmaceuticals including Teragase injection, a human-derived recombinant hyaluronidase, and is developing ALTS-OP01, a candidate for macular degeneration. [ 3 , 4 , 5 , 6 , 7 ]
The company said the merger integrates pipelines and business capabilities that had been spread across the subsidiary and strengthens a system running from research and development through commercialisation, and that it expects subsidiary pipeline results to be reflected more directly in corporate value. Chosun Ilbo reported the deal is intended to move the company away from a business structure centred on its subcutaneous injection formulation-change platform “ALT-B4” toward developing and directly selling its own drugs. Maeil Business, citing the company, said the focus is securing commercialisation capability and using the subsidiary's existing sales organisation to cut the time and burden of building one from scratch. An Alteogen official was quoted as calling the merger a turning point for expanding into development and commercialisation of its own products. [ 2 , 3 , 4 , 5 , 6 , 7 ]
On process, Alteogen said it set up a special committee of independent directors and used external legal and financial advisers and a securities underwriter. The committee reviewed the purpose and need for the merger, the valuation method and the impact on the company and all shareholders, and recommended the deal; the board approved it taking that recommendation into account. The two companies are to sign the merger contract on Oct 7, and the merger date is set for Dec 29. Alteogen will post merger materials and an FAQ online and open a channel for shareholder comments from Oct 7, and will hold a shareholder meeting in Daejeon on Oct 15 to explain the merger's purpose, expected effects and business plan; Alteogen Biologics will hold a shareholder meeting for its own shareholders on Oct 14. [ 3 , 4 , 5 , 6 , 7 ]
On the same day, Alteogen said it will raise 200 billion won from the National Growth Fund and SkyLake, with the money to go to building a new production facility and to introducing new products and technology. Maeil Business reported that part of the funds would go to a biopharmaceutical production facility in Daejeon, with the rest for new products and technology, and that the company plans to combine that production investment with the subsidiary's clinical, regulatory and sales capabilities. [ 1 , 7 ]
Почему это важно
Alteogen says the merger consolidates pipelines, clinical and regulatory experience and sales capability under the listed parent, moving it beyond licensing its platform technology toward developing and selling its own products, and that subsidiary pipeline results will be reflected more directly in corporate value. Shareholders get briefings on Oct 14 and 15 before a merger date set for Dec 29, and the company ties the deal to a same-day 200 billion won fundraising it says will fund production and new products.
Ключевые факты
- Alteogen's board decided on Oct 6 to absorb subsidiary Alteogen Biologics through a small-scale merger, the company disclosed. [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ]
- Alteogen holds a 62.9% stake in Alteogen Biologics. [ 3 , 4 , 5 , 6 , 7 ]
- The merger ratio is 1 to 0.1679581; 600,477 new Alteogen shares will be issued to Alteogen Biologics shareholders, and no new shares are allotted for Alteogen's 62.9% stake. [ 3 , 4 , 5 , 6 , 7 ]
- The two companies are to sign the merger contract on Oct 7, and the merger date is scheduled for Dec 29. [ 4 , 5 , 6 , 7 ]
- Alteogen Biologics holds the completed global phase 3 trial and European approval for Aylia biosimilar ALT-L9, handles sales and marketing of drugs including Teragase injection, and is developing the macular degeneration candidate ALTS-OP01. [ 3 , 4 , 5 , 6 , 7 ]
- A special committee of independent directors reviewed the merger with external legal and financial advisers and recommended it; the board approved it. [ 3 , 4 , 5 , 6 , 7 ]
- Alteogen will post merger materials and an FAQ online and open a shareholder feedback channel from Oct 7, hold a shareholder meeting in Daejeon on Oct 15, and Alteogen Biologics will hold its own on Oct 14. [ 3 , 7 ]
- Alteogen also said it will raise 200 billion won from the National Growth Fund and SkyLake, for a new production facility and new products and technology. [ 1 , 7 ]
Подтверждено несколькими источниками
- Alteogen's board decided on Oct 6 to absorb Alteogen Biologics through a small-scale merger, the company disclosed. [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ]
- Alteogen Biologics is a subsidiary 62.9% owned by Alteogen. [ 3 , 4 , 5 , 6 , 7 ]
- The merger ratio is 1 to 0.1679581; 600,477 new Alteogen shares will be issued to Alteogen Biologics shareholders, and no new shares are allotted for Alteogen's 62.9% stake. [ 3 , 4 , 5 , 6 , 7 ]
- The merger contract is to be signed on Oct 7, and the merger date is set for Dec 29. [ 4 , 5 , 6 , 7 ]
- Alteogen Biologics holds the completed global phase 3 trial and European approval for ALT-L9, an Aylia biosimilar, and is developing the macular degeneration candidate ALTS-OP01. [ 3 , 4 , 5 , 6 , 7 ]
- The merger was reviewed by a special committee of independent directors with external legal and financial advisers, which recommended it, and the board approved it. [ 3 , 4 , 5 , 6 , 7 ]
- Alteogen said the merger is aimed at integrating pipelines and business capabilities scattered across the subsidiary and strengthening a system that runs from research and development through commercialisation. [ 3 , 4 , 5 , 6 , 7 ]
- Alteogen will hold a shareholder meeting in Daejeon on Oct 15 and Alteogen Biologics will hold one on Oct 14. [ 3 , 7 ]
- Alteogen said it will raise 200 billion won from the National Growth Fund and SkyLake, to be spent on a new production facility and on new products and technology. [ 1 , 7 ]
Пока неясно
- The financial terms of the 200 billion won fundraising from the National Growth Fund and SkyLake. The documents give the amount, the investors and the intended uses but no valuation, stake or structure, and the item is reported mainly through company statements.
- Whether further regulatory or shareholder approvals are required for the merger. The documents describe the board decision and planned shareholder meetings but do not state approval requirements.
- The valuation of Alteogen Biologics beyond the merger ratio. The documents say the ratio was based on Alteogen's base price and an external valuation of Alteogen Biologics' intrinsic value but give no valuation figures.
- How Alteogen's platform is described. Chosun Ilbo refers to the subcutaneous injection formulation-change platform “ALT-B4”, while Asia Economy and Maeil Business refer to the “hybrozyme” platform; the documents do not state whether these are the same technology.
Что пишут местные СМИ
Хронология, местное время
- Korea Economic Daily publishes a report whose items include Alteogen's 200 billion won fundraising from the National Growth Fund and SkyLake. [ 1 ]
- Yonhap and Chosun Ilbo publish reports on the merger decision. [ 2 , 3 ]
- Newsis reports the merger, including the plan to sign the contract on Oct 7. [ 4 ]
- Seoul Economic Daily reports the merger and a company official's comments. [ 5 ]
- Asia Economy reports the merger and the Dec 29 merger date. [ 6 ]
- Maeil Business reports the merger together with the 200 billion won fundraising and the Daejeon production facility plan. [ 7 ]
- Korea Economic Daily publishes a second report on the merger. [ 8 ]
- Alteogen and Alteogen Biologics are scheduled to sign the merger contract; Alteogen begins posting merger materials and an FAQ online and opens a shareholder feedback channel. [ 3 , 4 , 5 , 6 , 7 ]
- Alteogen Biologics is scheduled to hold a shareholder meeting. [ 3 , 7 ]
- Alteogen is scheduled to hold a shareholder meeting in Daejeon to explain the merger's purpose, expected effects and business plan. [ 3 , 7 ]
- Scheduled merger date. [ 4 , 5 , 6 , 7 ]